US report finds flaws in FDA oversight of foreign clinical trials
This article was originally published in Scrip
Executive Summary
The US Department of Health and Human Services has called for the Food and Drug Administration to improve its oversight of foreign clinical trial data after finding that sponsors rely "heavily" on such data to support their marketing applications and a lack of foreign trial inspections by the agency.